Editing Serimmune antibody analysis results
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then save the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 1: | Line 1: | ||
− | |||
− | |||
[[File:Serimmunetypicalresults.png|alt=image of a sample result|thumb|Serimmune antibody test results sample.]] | [[File:Serimmunetypicalresults.png|alt=image of a sample result|thumb|Serimmune antibody test results sample.]] | ||
The [https://serimmune.com/covid19study/ Serimmune COVID-19 Study] is a longitudinal research study conducted by the Serimmune company. The study uses the company's "Serum Epitope Repertoire Analysis (SERA) technology" to study antibody responses, especially in the context of COVID-19 vaccination and exposure. | The [https://serimmune.com/covid19study/ Serimmune COVID-19 Study] is a longitudinal research study conducted by the Serimmune company. The study uses the company's "Serum Epitope Repertoire Analysis (SERA) technology" to study antibody responses, especially in the context of COVID-19 vaccination and exposure. | ||
− | + | The company pre-published<ref>High-resolution mapping and characterization of epitopes in COVID-19 patients | |
− | The | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
Winston A. Haynes, Kathy Kamath, Joel Bozekowski, Elisabeth Baum-Jones, Melissa Campbell, Arnau Casanovas-Massana, Patrick S. Daugherty, Charles S. Dela Cruz, Abhilash Dhal, Shelli F. Farhadian, Lynn Fitzgibbons, John Fournier, Michael Jhatro, Gregory Jordan, Debra Kessler, Jon Klein, Carolina Lucas, Larry L. Luchsinger, Brian Martinez, Mary C. Muenker, Lauren Pischel, Jack Reifert, Jaymie R. Sawyer, Rebecca Waitz, Elsio A. Wunder Jr., Minlu Zhang, Yale IMPACT Team, Akiko Iwasaki, Albert I. Ko, John C. Shon | Winston A. Haynes, Kathy Kamath, Joel Bozekowski, Elisabeth Baum-Jones, Melissa Campbell, Arnau Casanovas-Massana, Patrick S. Daugherty, Charles S. Dela Cruz, Abhilash Dhal, Shelli F. Farhadian, Lynn Fitzgibbons, John Fournier, Michael Jhatro, Gregory Jordan, Debra Kessler, Jon Klein, Carolina Lucas, Larry L. Luchsinger, Brian Martinez, Mary C. Muenker, Lauren Pischel, Jack Reifert, Jaymie R. Sawyer, Rebecca Waitz, Elsio A. Wunder Jr., Minlu Zhang, Yale IMPACT Team, Akiko Iwasaki, Albert I. Ko, John C. Shon | ||
− | medRxiv 2020.11.23.20235002; doi: <nowiki>https://doi.org/10.1101/2020.11.23.20235002</nowiki></ref> | + | medRxiv 2020.11.23.20235002; doi: <nowiki>https://doi.org/10.1101/2020.11.23.20235002</nowiki></ref> the technical details behind their platform. |
− | + | The study returns research-grade results (not intended for diagnostic clinical use) to participants. As described in the [https://serimmune.com/caspio-content/COVID-19-Study-Consent-Form-and-Bill-of-Rights-Preview.pdf study consent document], these results are not clinically validated and not meant to serve as a clinical assay. They are, nevertheless, interesting to look at! | |
− | + | The study is planned to last five years, with blood samples collected every six months. Samples are self-collected by participants using a home collection kit and sent by mail. | |
− | + | {{Project Infobox|Self researchers=User:Madprime,User:Sprague |Related tools= |Related topics= }} | |
− | + | =SARS-CoV-2 Antibody Analyses= | |
− | = | + | ==Vaccine-only responses== |
− | + | {| class="wikitable" | |
− | |||
− | {| class="wikitable | ||
|- | |- | ||
− | ! Individual | + | ! Individual !! Date !! Report !! Notes |
− | ! Date | ||
− | ! | ||
− | |||
− | ! | ||
− | ! | ||
|- | |- | ||
− | | [[User: | + | | [[User:Madprime]] || 2022-02-03 || [[File:TOEAIX_20220203.pdf]] || Moderna vaccine (two shots, plus booster) |
|- | |- | ||
− | | [[User: | + | | [[User:Sprague]] || |2021-12-14 || [[File:RichardSpragueSerimmuneCOVID 20211214.pdf]] || Pfizer vaccine (two shots, no booster) |
|- | |- | ||
− | | [[User: | + | | [[User:Igerg]] || 2022-04-13 || [[File:EXACZL_20220413.pdf]] || Moderna vaccine (two shots, plus booster) - chronic spontaneous urticaria following booster |
|- | |- | ||
− | | [[User: | + | | [[User:EricJain]] || 2022-01-20, 2022-07-21 || [[File:EricJain-Serimmune-20220721.pdf]] || 2021-04-21 (Pfizer), 2021-05-12 (Pfizer), 2021-12-08 (Pfizer) |
+ | |} | ||
+ | |||
+ | ==Post-exposure responses== | ||
+ | |||
+ | [[File:Before_and_after_covid_antibody_results.png|alt=image of results before and after covid infection|thumb|Serimmune results before and after natural covid infection in a previously-vaccinated individual.]] | ||
+ | |||
+ | {| class="wikitable" | ||
|- | |- | ||
− | + | ! Individual !! Date !! Report !! Notes | |
|- | |- | ||
− | | [[User: | + | | [[ User:Madprime]] || 2022-05-27 || [[File:TOEAIX_20220527.pdf]] || Covid positive on 2022-05-01. Previously vaccinated with booster. |
|} | |} | ||
− | |||
= Other results= | = Other results= | ||
Line 60: | Line 49: | ||
|- | |- | ||
!Individual!!Date!!Report!!Notes | !Individual!!Date!!Report!!Notes | ||
+ | |- | ||
+ | | [[User:Madprime]]||2022-02-03||[[File:TOEAIX_Expanded_20220203.pdf]]||No medical history related to these analyses. | ||
|- | |- | ||
| [[User:Sprague]] || 2021-12-14 ||[[File:RichardSpragueSerimmune_20211214.pdf]] || | | [[User:Sprague]] || 2021-12-14 ||[[File:RichardSpragueSerimmune_20211214.pdf]] || | ||
− | |||
− | |||
|- | |- | ||
| [[User:Igerg]] || 2022-04-13 || [[File:EXACZL_Additional_20220413.pdf]] || Tested for Lyme several times, all negative | | [[User:Igerg]] || 2022-04-13 || [[File:EXACZL_Additional_20220413.pdf]] || Tested for Lyme several times, all negative | ||
|- | |- | ||
| [[User:Madprime]] || 2022-05-27 || [[File:TOEAIX_Additional_20220527.pdf]] || | | [[User:Madprime]] || 2022-05-27 || [[File:TOEAIX_Additional_20220527.pdf]] || | ||
− | |||
− | |||
|} | |} | ||
− | + | {{Project Queries}} | |
[[Category:Projects]] | [[Category:Projects]] |